Limits...
Dopaminergic therapy in Parkinson's disease decreases cortical beta band coherence in the resting state and increases cortical beta band power during executive control.

George JS, Strunk J, Mak-McCully R, Houser M, Poizner H, Aron AR - Neuroimage Clin (2013)

Bottom Line: Dopaminergic medication reduced this coherence.Off medication increased beta band power over right frontal cortex for successful stopping and over bilateral sensorimotor cortex for going, especially for those patients who showed greater clinical improvement.Thus, medication reduced pathological coherence in beta band at rest and increased task related beta power for two potentially dissociable cortico-basal ganglia circuits.

View Article: PubMed Central - PubMed

Affiliation: Department of Psychology, University of California San Diego, USA.

ABSTRACT
It is not yet well understood how dopaminergic therapy improves cognitive and motor function in Parkinson's disease (PD). One possibility is that it reduces the pathological synchronization within and between the cortex and basal ganglia, thus improving neural communication. We tested this hypothesis by recording scalp electroencephalography (EEG) in PD patients when On and Off medication, during a brief resting state epoch (no task), and during performance of a stop signal task that is thought to engage two partially overlapping (or different) frontal-basal-ganglia circuits. For resting state EEG, we measured pair-wise coherence between scalp electrodes in several frequency bands. Consistent with previous studies, in the Off medication state, those patients with the greatest clinical impairment had the strongest coherence, especially in the beta band, indicating pathological over-synchronization. Dopaminergic medication reduced this coherence. For the stop signal task, On vs. Off medication increased beta band power over right frontal cortex for successful stopping and over bilateral sensorimotor cortex for going, especially for those patients who showed greater clinical improvement. Thus, medication reduced pathological coherence in beta band at rest and increased task related beta power for two potentially dissociable cortico-basal ganglia circuits. These results support the hypothesis that dopaminergic medication in PD improves neural communication both at rest and for executive and motor function.

No MeSH data available.


Related in: MedlinePlus

Stop signal task results A. Mean Go RTs for controls and patients On and Off medication. There is no significant difference between the groups. B. Mean SSRTs for controls and patients On and Off medication. There are significant differences between the controls and patients On medication (t30 = 2.07, P < 0.05); as well as between the controls and patients Off medication sessions (t30 = 2.47, P < 0.05).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3814961&req=5

f0015: Stop signal task results A. Mean Go RTs for controls and patients On and Off medication. There is no significant difference between the groups. B. Mean SSRTs for controls and patients On and Off medication. There are significant differences between the controls and patients On medication (t30 = 2.07, P < 0.05); as well as between the controls and patients Off medication sessions (t30 = 2.47, P < 0.05).

Mentions: The patients took significantly longer to stop their responses than controls as SSRT was longer (On vs. controls: t30 = 2.07, P < 0.05; Off vs. controls: t30 = 2.47, P < 0.05). However, there was no difference in SSRT for On vs. Off (P > 0.6) (Table 3; Fig. 3B). Thus, dopaminergic treatment did not improve the patients' stopping ability.


Dopaminergic therapy in Parkinson's disease decreases cortical beta band coherence in the resting state and increases cortical beta band power during executive control.

George JS, Strunk J, Mak-McCully R, Houser M, Poizner H, Aron AR - Neuroimage Clin (2013)

Stop signal task results A. Mean Go RTs for controls and patients On and Off medication. There is no significant difference between the groups. B. Mean SSRTs for controls and patients On and Off medication. There are significant differences between the controls and patients On medication (t30 = 2.07, P < 0.05); as well as between the controls and patients Off medication sessions (t30 = 2.47, P < 0.05).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3814961&req=5

f0015: Stop signal task results A. Mean Go RTs for controls and patients On and Off medication. There is no significant difference between the groups. B. Mean SSRTs for controls and patients On and Off medication. There are significant differences between the controls and patients On medication (t30 = 2.07, P < 0.05); as well as between the controls and patients Off medication sessions (t30 = 2.47, P < 0.05).
Mentions: The patients took significantly longer to stop their responses than controls as SSRT was longer (On vs. controls: t30 = 2.07, P < 0.05; Off vs. controls: t30 = 2.47, P < 0.05). However, there was no difference in SSRT for On vs. Off (P > 0.6) (Table 3; Fig. 3B). Thus, dopaminergic treatment did not improve the patients' stopping ability.

Bottom Line: Dopaminergic medication reduced this coherence.Off medication increased beta band power over right frontal cortex for successful stopping and over bilateral sensorimotor cortex for going, especially for those patients who showed greater clinical improvement.Thus, medication reduced pathological coherence in beta band at rest and increased task related beta power for two potentially dissociable cortico-basal ganglia circuits.

View Article: PubMed Central - PubMed

Affiliation: Department of Psychology, University of California San Diego, USA.

ABSTRACT
It is not yet well understood how dopaminergic therapy improves cognitive and motor function in Parkinson's disease (PD). One possibility is that it reduces the pathological synchronization within and between the cortex and basal ganglia, thus improving neural communication. We tested this hypothesis by recording scalp electroencephalography (EEG) in PD patients when On and Off medication, during a brief resting state epoch (no task), and during performance of a stop signal task that is thought to engage two partially overlapping (or different) frontal-basal-ganglia circuits. For resting state EEG, we measured pair-wise coherence between scalp electrodes in several frequency bands. Consistent with previous studies, in the Off medication state, those patients with the greatest clinical impairment had the strongest coherence, especially in the beta band, indicating pathological over-synchronization. Dopaminergic medication reduced this coherence. For the stop signal task, On vs. Off medication increased beta band power over right frontal cortex for successful stopping and over bilateral sensorimotor cortex for going, especially for those patients who showed greater clinical improvement. Thus, medication reduced pathological coherence in beta band at rest and increased task related beta power for two potentially dissociable cortico-basal ganglia circuits. These results support the hypothesis that dopaminergic medication in PD improves neural communication both at rest and for executive and motor function.

No MeSH data available.


Related in: MedlinePlus